Trial Profile

An International Multicenter Randomized Double-blind Placebo-controlled Clinical Study of the Efficacy and Safety of Subcutaneous BCD-085 in Patients With Psoriatic Arthritis

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 11 Sep 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

05 Jun 2021 Results of subanalysis; assessing ACR (American College of Rheumatology) 20/50/70 response rate in PsA patients with/without the axial disease, presented at the 22nd Annual Congress of the European League Against Rheumatism
05 Jun 2021 Results of subanalysis assessing effect of Netakimab on domains of EQ-5D-5L in patients with inflammatory back pain and without at baseline presented at the 22nd Annual Congress of the European League Against Rheumatism
21 Jul 2020 Planned End Date changed from 31 Jan 2021 to 1 Nov 2022.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com